Orally active non-steroidal androgen receptor antagonist (IC50 = 190 nM). Displays peripheral selectivity and does not effect serum levels of LH and testosterone. Exhibits potent anticancer activity in vivo.
Sold for research purposes only under agreement from AstraZeneca
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 430.37. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.32 mL||11.62 mL||23.24 mL|
|5 mM||0.46 mL||2.32 mL||4.65 mL|
|10 mM||0.23 mL||1.16 mL||2.32 mL|
|50 mM||0.05 mL||0.23 mL||0.46 mL|
References are publications that support the products' biological activity.
Furr et al (1987) ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen. J.Endocrinol. 113 R7 PMID: 3625091
Tucker et al (1988) Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides. J.Med.Chem. 31 954 PMID: 3361581
Furr and Tucker (1996) The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology 47 13 PMID: 8560673
If you know of a relevant reference for Bicalutamide, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Bicalutamide, supplier, Non-steroidal, Androgen, receptor, antagonists, Dihydrotestosterone, Receptors, AstraZeneca, ICI176,334, chemotherapeutics, Casodex, ICI, 176,334, Androgen, Receptor, Androgen, Receptor, Tocris Bioscience
3 Citations for Bicalutamide
Citations are publications that use Tocris products. Selected citations for Bicalutamide include:
Ivachtchenko et al (2014) Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment. PLoS One 5 133 PMID: 24494031
Ishizaki et al (2013) Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer. Sci Rep 3 1528 PMID: 23524847
Gambara et al (2015) TLR3 engagement induces IRF-3-dependent apoptosis in androgen-sensitive prostate cancer cells and inhibits tumour growth in vivo. J Cell Mol Med 19 327 PMID: 25444175
Do you know of a great paper that uses Bicalutamide from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)